thalidomide has been researched along with Granulocytic Leukemia, Chronic in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide treatment (400 mg/day), however, dramatically improved the colitis within 7 days: fever and diarrhoea disappearing." | 5.29 | Treatment of colitis in Behçet's disease with thalidomide. ( den Haan, P; Postema, PT; van Blankenstein, M; van Hagen, PM, 1996) |
| " The patient re-achieved molecular remission after resumption of imatinib, but his MGUS progressed to smoldering myeloma and he was eventually diagnosed with multiple myeloma (MM) and initiated on treatment for MM with thalidomide, bortezomib and dexamethasone." | 3.96 | Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient. ( Dourado, C; Gupta, S; Swaminathan, N, 2020) |
| "Lenalidomide is a second-generation oral immunomodulatory drug that has been broadly applied in the treatment of various hematological malignancies." | 1.48 | Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report. ( Lai, B; Mu, Q; Ouyang, G; Sheng, L; Wang, Y; Xu, K; Zhang, Y; Zhu, H, 2018) |
| "The abnormal cell types in chronic myeloid leukemia (CML) and monoclonal gammopathy of uncertain (MGUS) are quite different, being myeloid and plasma cells, respectively." | 1.48 | Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report. ( Lu, S; Ouyang, W; Wang, Z; Zhao, X, 2018) |
| "A 46-year-old woman with chronic myelogenous leukemia who had received an allogeneic HSCT previously from an HLA-identical sibling, presented on day +814 with human herpes virus-8-associated KS involving her left lower extremity." | 1.31 | Kaposi's sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. ( Bilgrami, S; Bona, RD; de Medeiros , BC; Edwards, RL; Feingold, JM; Rezuke, WN; Ricci, A; Shen, PU; Tsongalis, G; Tutschka, PJ, 2000) |
| "Thalidomide treatment (400 mg/day), however, dramatically improved the colitis within 7 days: fever and diarrhoea disappearing." | 1.29 | Treatment of colitis in Behçet's disease with thalidomide. ( den Haan, P; Postema, PT; van Blankenstein, M; van Hagen, PM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Swaminathan, N | 2 |
| Gupta, S | 2 |
| Dourado, C | 2 |
| Lai, B | 1 |
| Mu, Q | 1 |
| Zhu, H | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Xu, K | 1 |
| Sheng, L | 1 |
| Ouyang, G | 1 |
| Ouyang, W | 1 |
| Zhao, X | 1 |
| Lu, S | 1 |
| Wang, Z | 1 |
| Vico-Alonso, C | 1 |
| Sánchez-Velázquez, A | 1 |
| Pinilla-Martin, B | 1 |
| Andrés-Lencina, JJ | 1 |
| Aragón-Miguel, R | 1 |
| Calleja-Algarra, A | 1 |
| Rivera-Díaz, R | 1 |
| Abdel-Wahab, O | 1 |
| Pardanani, A | 1 |
| Bernard, OA | 1 |
| Finazzi, G | 1 |
| Crispino, JD | 1 |
| Gisslinger, H | 1 |
| Kralovics, R | 1 |
| Odenike, O | 1 |
| Bhalla, K | 1 |
| Gupta, V | 1 |
| Barosi, G | 1 |
| Gotlib, J | 1 |
| Guglielmelli, P | 1 |
| Kiladjian, JJ | 1 |
| Noel, P | 1 |
| Cazzola, M | 1 |
| Vannucchi, AM | 1 |
| Hoffman, R | 1 |
| Barbui, T | 1 |
| Thiele, J | 1 |
| Van Etten, RA | 1 |
| Mughal, T | 1 |
| Tefferi, A | 1 |
| Rechner, I | 1 |
| Brito-Babapulle, F | 1 |
| Fielden, J | 1 |
| Staumont-Sallé, D | 1 |
| Magro, L | 1 |
| Piette, F | 1 |
| Thomas, P | 1 |
| Jouet, JP | 1 |
| Catteau, B | 1 |
| Ergun, MA | 1 |
| Konac, E | 1 |
| Erbas, D | 1 |
| Ekmekci, A | 1 |
| Nair, V | 1 |
| Sharma, A | 1 |
| Ghosh, I | 1 |
| Arora, S | 1 |
| Sahai, K | 1 |
| Dutta, V | 1 |
| Platzbecker, U | 1 |
| Mohr, B | 1 |
| von Bonin, M | 1 |
| Binder, M | 1 |
| Schetelig, J | 1 |
| Ehninger, G | 1 |
| Bornhäuser, M | 1 |
| Nishimura, K | 1 |
| Hashimoto, Y | 1 |
| Iwasaki, S | 1 |
| Postema, PT | 1 |
| den Haan, P | 1 |
| van Hagen, PM | 1 |
| van Blankenstein, M | 1 |
| de Medeiros , BC | 1 |
| Rezuke, WN | 1 |
| Ricci, A | 1 |
| Tsongalis, G | 1 |
| Shen, PU | 1 |
| Bona, RD | 1 |
| Feingold, JM | 1 |
| Edwards, RL | 1 |
| Tutschka, PJ | 1 |
| Bilgrami, S | 1 |
| Hatfill, SJ | 1 |
| Fester, ED | 1 |
| de Beer, DP | 1 |
| Bohm, L | 1 |
14 other studies available for thalidomide and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.
Topics: Acute Disease; Antineoplastic Agents; Drug Therapy, Combination; Humans; Induction Chemotherapy; Len | 2018 |
Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report.
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mo | 2018 |
Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; M | 2020 |
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
Topics: Clinical Trials as Topic; Disease Progression; DNA Methylation; DNA, Neoplasm; Drugs, Investigationa | 2012 |
Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Combined Modality Th | 2003 |
Chronic graft-versus-host disease revealed by lichenoid vulvar lesions successfully treated with thalidomide.
Topics: Administration, Oral; Adult; Bone Marrow Transplantation; Diagnosis, Differential; Female; Graft vs | 2003 |
Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells.
Topics: Apoptosis; Contraceptive Agents, Male; Dexamethasone; Dose-Response Relationship, Drug; Glucocortico | 2004 |
Extensive chronic graft-versus-host disease of skin successfully treated with thalidomide.
Topics: Adult; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chron | 2005 |
Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.
Topics: Aged; Antineoplastic Agents; Cell Proliferation; Chromosomes, Human, Pair 5; Cytogenetics; Early Gro | 2007 |
Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide.
Topics: Cell Line; Drug Synergism; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuke | 1994 |
Treatment of colitis in Behçet's disease with thalidomide.
Topics: Adult; Behcet Syndrome; Colitis; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, B | 1996 |
Kaposi's sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
Topics: Administration, Oral; Administration, Topical; Adult; Alitretinoin; Antineoplastic Agents; Child; Fe | 2000 |
Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites.
Topics: Animals; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Agents; Blast Crisis; Cell Differenti | 1991 |